Chris Howerton
Stock Analyst at Jefferies
(2.65)
# 1,948
Out of 5,182 analysts
66
Total ratings
44.23%
Success rate
20.32%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Chris Howerton
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VNDA Vanda Pharmaceuticals | Maintains: Hold | $5 → $7.5 | $6.79 | +10.46% | 12 | Dec 31, 2025 | |
| GPCR Structure Therapeutics | Maintains: Buy | $79 → $125 | $45.33 | +175.76% | 3 | Dec 11, 2025 | |
| ARDX Ardelyx | Maintains: Buy | $11 → $8 | $5.99 | +33.56% | 5 | Jan 2, 2025 | |
| MIST Milestone Pharmaceuticals | Downgrades: Hold | $8 → $4 | $1.86 | +115.05% | 4 | Jun 20, 2023 | |
| VERU Veru Inc. | Upgrades: Hold | $10 | $2.34 | +327.35% | 3 | Jun 7, 2023 | |
| BTAI BioXcel Therapeutics | Downgrades: Hold | $320 → $352 | $1.09 | +32,193.58% | 2 | Mar 10, 2023 | |
| AVTX Avalo Therapeutics | Downgrades: Underperform | $720 | $14.42 | +4,893.07% | 2 | Feb 8, 2023 | |
| CGEN Compugen | Downgrades: Underperform | $0.5 | $2.92 | -82.88% | 2 | Feb 8, 2023 | |
| URGN UroGen Pharma | Downgrades: Hold | $35 → $10 | $23.77 | -57.93% | 1 | Feb 8, 2023 | |
| APLS Apellis Pharmaceuticals | Downgrades: Hold | $70 → $40 | $40.95 | -2.32% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $57 → $61 | $31.05 | +96.46% | 3 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $92 → $90 | $187.40 | -51.97% | 3 | Sep 30, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $66 | $33.66 | +96.08% | 9 | Sep 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $6.29 | +249.76% | 1 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $1.31 | +1,503.05% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $0.83 | +2,550.60% | 1 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $40 → $21 | $22.30 | -5.83% | 6 | Apr 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $80 → $580 | $7.32 | +7,823.50% | 2 | Aug 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $63 → $60 | $2.07 | +2,798.55% | 1 | Aug 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $16 | $46.22 | -65.38% | 2 | Aug 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $98.51 | -72.59% | 1 | Jul 15, 2020 |
Vanda Pharmaceuticals
Dec 31, 2025
Maintains: Hold
Price Target: $5 → $7.5
Current: $6.79
Upside: +10.46%
Structure Therapeutics
Dec 11, 2025
Maintains: Buy
Price Target: $79 → $125
Current: $45.33
Upside: +175.76%
Ardelyx
Jan 2, 2025
Maintains: Buy
Price Target: $11 → $8
Current: $5.99
Upside: +33.56%
Milestone Pharmaceuticals
Jun 20, 2023
Downgrades: Hold
Price Target: $8 → $4
Current: $1.86
Upside: +115.05%
Veru Inc.
Jun 7, 2023
Upgrades: Hold
Price Target: $10
Current: $2.34
Upside: +327.35%
BioXcel Therapeutics
Mar 10, 2023
Downgrades: Hold
Price Target: $320 → $352
Current: $1.09
Upside: +32,193.58%
Avalo Therapeutics
Feb 8, 2023
Downgrades: Underperform
Price Target: $720
Current: $14.42
Upside: +4,893.07%
Compugen
Feb 8, 2023
Downgrades: Underperform
Price Target: $0.5
Current: $2.92
Upside: -82.88%
UroGen Pharma
Feb 8, 2023
Downgrades: Hold
Price Target: $35 → $10
Current: $23.77
Upside: -57.93%
Apellis Pharmaceuticals
Nov 10, 2022
Downgrades: Hold
Price Target: $70 → $40
Current: $40.95
Upside: -2.32%
Oct 14, 2022
Upgrades: Buy
Price Target: $57 → $61
Current: $31.05
Upside: +96.46%
Sep 30, 2022
Maintains: Buy
Price Target: $92 → $90
Current: $187.40
Upside: -51.97%
Sep 17, 2021
Initiates: Buy
Price Target: $66
Current: $33.66
Upside: +96.08%
Aug 23, 2021
Initiates: Buy
Price Target: $22
Current: $6.29
Upside: +249.76%
Aug 10, 2021
Initiates: Buy
Price Target: $21
Current: $1.31
Upside: +1,503.05%
May 25, 2021
Initiates: Buy
Price Target: $22
Current: $0.83
Upside: +2,550.60%
Apr 6, 2021
Downgrades: Hold
Price Target: $40 → $21
Current: $22.30
Upside: -5.83%
Aug 11, 2020
Upgrades: Buy
Price Target: $80 → $580
Current: $7.32
Upside: +7,823.50%
Aug 7, 2020
Downgrades: Underperform
Price Target: $63 → $60
Current: $2.07
Upside: +2,798.55%
Aug 5, 2020
Downgrades: Hold
Price Target: $16
Current: $46.22
Upside: -65.38%
Jul 15, 2020
Initiates: Buy
Price Target: $27
Current: $98.51
Upside: -72.59%